Cost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy -

Cost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy
Information type: Other primary research
Source: BMJ Open
Specialities: Cancers
Summary
In patients with stage IIIb–IV NSCLC deemed unsuitable for chemotherapy, the mean incremental cost-effectiveness ratio for first-line erlotinib was estimated as £202,571/QALY. However in those who developed a first cycle rash, it was lower at £56,770/QALY.
UKMi comment
In guidance issued in June 2012 (TA258), NICE recommends erlotinib as an option for the first-line treatment of people with locally advanced or metastatic NSCLC if they test positive for the epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation and the manufacturer provides erlotinib at the discounted price agreed under the patient access scheme.
Related links: NICE guidance (TA258)